Is age ≥70years an important predictor of adverse events among patients enrolled in metastatic melanoma trials? Findings from pooled analyses of therapeutic trials

Aminah Jatoi, Jacob B. Allred, Vera J. Suman, Edward T. Creagan, Gary A. Croghan, Thomas Amatruda, Svetomir N. Markovic

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint Dive into the research topics of 'Is age ≥70years an important predictor of adverse events among patients enrolled in metastatic melanoma trials? Findings from pooled analyses of therapeutic trials'. Together they form a unique fingerprint.

Medicine & Life Sciences